News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
BioDelivery Sciences International Anticipates Announcing Phase III BEMA Fentanyl Efficacy Data In April
February 8, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq:BDSI) plans to report Phase III data in April, regarding the efficacy of BEMA Fentanyl in the treatment of breakthrough pain in cancer patients.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
MORE ON THIS TOPIC
Antibody-drug conjugate (ADC)
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
May 22, 2026
·
3 min read
·
Annalee Armstrong
Parkinson’s disease
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop
May 22, 2026
·
2 min read
·
Tristan Manalac
Postmarket research
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
May 21, 2026
·
3 min read
·
Tristan Manalac
Weight loss
Lilly’s triple agonist shows bariatric surgery–like weight loss results
May 21, 2026
·
3 min read
·
Annalee Armstrong
